Objective To compare the effectiveness of melarsoprol and eflornithine in treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Methods We analysed the outcomes of death during treatment and relapse within 1 year of discharge for 288 patients treated with eflornithine, 311 patients treated with the standard melarsoprol regimen and 62 patients treated with a short-course (10-day) melarsoprol regimen between April 2001 and April 2005. Findings A total of 1.7% (5/288) of patients treated with eflornithine died compared with 4.8% (15/311) of those treated with standard melarsoprol and 6.5% (4/62) of those treated with short-course melarsoprol. Patients treated with eflornithine tended to be younger and were more likely to have trypanosomes or higher white blood cell counts in their cerebrospinal fluid. The cumulated incidence of relapse among patients who attended at least one follow-up visit 1 year after discharge was 8.1% (11/136) for those treated with eflornithine, 14% (36/258) for those treated with standard melarsoprol and 15.5% (9/58) for those treated with shortcourse melarsoprol. In a multivariate analysis, when compared with eflornithine, standard melarsoprol was found to be a risk factor for both death (odds ratio (OR) = 2.87; 95% confidence interval (CI) = 1.03-8.00) and relapse (hazard ratio (HR) = 2.47; 95% CI = 1.22-5.03); when compared with eflornithine, short-course melarsoprol was also found to be a risk factor for death (OR = 3.90; 95% CI = 1.02-14.98) and relapse (HR = 6.65; 95% CI = 2.61-16.94). Conclusion The effectiveness of melarsoprol treatment appears to have diminished. Eflornithine seems to be a better first-line therapy for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. 
Introduction
African trypanosomiasis is a public health hazard in many countries in sub-Saharan Africa, with an incidence of around 20 000 new cases a year. 1, 2 The disease is fatal if untreated. Control programmes have been severely weakened by war and civil instability in many of the countries with the highest prevalence. 3, 4 In central and west Africa the disease is predominantly caused by the protozoan Trypanosoma brucei gambiense and is transmitted by the tsetse fly (Glossina spp.) in a human-fly-human cycle. Pentamidine, first-line treatment for early-stage disease, cannot be used if the parasites have invaded the central nervous system because the drug does not cross the blood-brain barrier. The principal treatment options for late-stage (or stage-2) disease are either melarsoprol (an organoarsenic compound that in--hibits parasite glycolysis) or eflornithine .
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(an irreversible inhibitor of ornithine decarboxylase which is necessary for the parasite's synthesis of DNA and RNA). Both drugs must be adminis--tered intravenously over a period of 1-4 weeks, which is logistically challenging in health-care systems in the developing world. Melarsoprol is a highly toxic drug that causes encephalopathy in 5-10% of patients and approximately 40% of these patients will die. 1, 5 Eflornithine produces a reversible pancytopenia but otherwise appears to be safer than melarsoprol. 6 Clinical research into new therapeu--tic options for treating late-stage disease remains limited and is conducted by only a few national programmes, research institutions and nongovernmental or--ganizations. Because it is unlikely that there will be any new molecules available in the next few years to treat late-stage disease, recent research has focused on optimizing the therapeutic regimens of the two registered drugs as well as on developing a combination treatment in--volving a third drug, nifurtimox, which is unregistered to treat late-stage African trypanosomiasis but is available for compassionate use. 4, [7] [8] [9] [10] [11] [12] The lack of new therapeutic options makes it crucial to monitor the use and effectiveness of the drug regimens currently being used.
Resistance to melarsoprol has been documented since the 1970s, but the majority of these reports come from east Africa. 13, 14 Health departments in countries in central and west Africa, in--cluding Angola, Côte d'Ivoire and the Republic of the Congo, still recommend melarsoprol as first-line therapy for late-stage disease, although Angola has documented resistance to the drug. 15 In the Republic of the Congo, fol--lowing a period of civil war in the 1990s, Médecins Sans Frontières (MSF) assisted the Ministry of Health in implementing 16 This was accompanied by a formal change in the programme's protocol in 2003. 16, 17 Both melarsoprol and eflornithine were available throughout the dura--tion of the programme but melarsoprol remained the first-line therapy until August 2003; eflornithine was reserved for patients whom clinicians felt were too ill for melarsoprol. Internal analysis of the MSF programme results at this time led to eflornithine becoming the first-line therapy at all MSF sites as a result of a high case-fatality rate and relapse rate among patients treated with melarsoprol: 3/46 (6.5%) patients treated with eflornithine died or relapsed compared with 46/429 (10.7%) treated with melarsoprol. For the majority of patients melarsoprol was administered according to the standard regimen, al--though the short-course 10-day regimen was used to treat a minority of patients (Fig. 1) . Details of the various treatment regimens are given in Table 1 .
For a patient's data to be included in the study the patient had to have been diagnosed with late-stage disease using the standard national protocol algorithm, had to have had no previous treatment for the disease, and had to have been admitted to an MSF treatment centre between April 2001 and April 2005. 
Statistical analysis Death during treatment
We investigated potential risk factors for death due to any cause during the first 30 days after admission among patients with late-stage disease. We excluded from this analysis patients who were enrolled in an ongoing equivalence trial of eflornithine plus nifurtimox, had been treated with regimens other than me--larsoprol (standard or short-course) or eflornithine, or for whom key baseline variables, such as age, sex, parasitological findings and treatment outcome, had not been reported. First, we explored the univariate as--sociations between death and potential risk factors (sex, age, screening mode -those cases identified by mobile teams in villages were denoted as active and those who self-presented at fixed screening posts were denoted as passive, technique on which parasitological confirmation was based, presence of trypanosomes in the cerebrospinal fluid, cerebrospinal fluid white cell count and drug regimen) and potential confound--ers (site, project period -that is, before or after eflornithine was used as first-line treatment in August 2003) by calculat--ing crude odds ratios (OR). We then fit a multivariate logistic regression model to adjust for the effects of confounding. Variables were entered into the model if they were associated with the outcome at the P < 0.20 level in the univariate analysis, and we gradually eliminated variables with nonsignificant multi--variate associations (P > 0.05); we per--formed likelihood ratio tests after each elimination, until we reached the final reduced model. We tested the model's assumptions, including the correctness of specification and goodness of fit.
Relapse
To make best use of the data (consist--ing of observations from patients with varying durations of follow-up), we used survival analysis to investigate risk factors for treatment failure during the first year of follow-up. We computed univariate hazard ratios (HR) for failure as described in the section on "Death during treatment", and then used Cox proportional hazards regression to adjust for confounders in a multivariate model. In addition to the exclusion criteria, we also excluded from this analysis all pa--tients who were admitted less than 1 year before closure of the MSF programme or who did not attend at least one follow-up visit in the first year after discharge. We restricted our analysis to the first year of follow-up, since follow-up rates were unacceptably low for longer periods. We considered any visit after discharge occurring from month 10 (day 304) to month 14 (day 425) as a valid 1-year follow-up visit.
We defined relapse (or failure to have been cured at 1 year) as: death due to any cause after discharge, recurrence of parasites in any body fluid, white cell count in cerebrospinal fluid >50 cells/ mm³ and at least doubled from the pre--vious measurement, or white cell count in cerebrospinal fluid 20-49 cells/mm³ with a significant increase from the pre--vious measurement and/or symptoms suggestive of disease.
We calculated the person-time under observation as the time between discharge and treatment failure or loss to follow-up if these occurred before day 425 after discharge or the 1-year follow-up date for patients for whom treatment had not failed and who had not left before treatment was completed. The model was constructed as described in the previous section. We also tested for interactions among covariates and between covariates and time (propor--tional hazards assumption).
Data collection and analysis
Personal, laboratory, treatment and out--come data from source documents were entered into a Microsoft Excel database (in Gamboma) or YoTryps (in Bouenza and Mossaka), a Microsoft Access-based software program specifically designed for African trypanosomiasis programmes by MSF, at programme locations. Data were analysed using Stata software ver--sion 8.0 (Stata Corp, College Station, Texas, USA).
Ethical approval
The study was a retrospective analysis of data from Médecins Sans Frontières' op--erational medical work in the Republic of the Congo. Approval for data exporta--tion, analysis and reporting was obtained from the Ministry of Health's national control programme in the Republic of the Congo. The datasets extracted and used for analysis were anonymized by removing all patients' names, separating the data into a new dataset, and having the data analysed by a statistician uncon--nected with the programmes. The treatment groups differed sig--nificantly (P < 0.001) in all baseline characteristics except for sex ratio and screening mode (Table 2) . Patients treated with eflornithine were on aver--age younger, were more likely to have trypanosomes in their cerebrospinal fluid and had higher white cell counts in their cerebrospinal fluid.
Findings
The case-fatality rate during treat--ment was lower in the eflornithine group (P = 0.060). Follow-up rates and median person-time under observation were comparable between the eflorni--thine group and the standard melar--soprol group but significantly shorter (P < 0.001) in the short-course melarso--prol group, in which only 20.7% (12/58) of patients attended the 1-year follow-up visit (Table 2) . Among the 452 patients admitted more than 1 year before the programme ended and discharged alive, those who did not attend the 1-year follow-up visit differed significantly The cumulated incidence of relapse was nonsignificantly lower in the eflorni--thine group (P = 0.084 for eflornithine versus standard melarsoprol regimen; P = 0.087 for eflornithine versus shortcourse melarsoprol). No obvious cluster--ing of relapses in time or by treatment centre was evident.
Multivariate analysis
The treatment centre, project period and diagnostic technique were weakly asso--ciated with death among late-stage pa--tients in the univariate analysis, but drug regimen emerged as the only significant risk factor in the final multivariate model (Table 3) . Compared with patients re--ceiving eflornithine, patients treated with standard-regimen melarsoprol had an adjusted OR of dying of 2.87 (P = 0.04), while those treated with shortcourse melarsoprol had an adjusted OR of 3.90 (P = 0.05). Confidence intervals for these associations were wide, rang--ing from almost no effect to an 8-fold increase in risk for standard melarsoprol and a 15-fold increase for short-course melarsoprol.
Baseline cerebrospinal fluid white cell counts and drug regimen were the only significant risk factors for relapse among patients with late-stage disease within 1 year after discharge in both the univariate and multivariate analyses ( Table 4 ). Both a high white cell count in cerebrospinal fluid and melarsoprol therapy (compared with eflornithine) increased the risk of relapse. When the project period was retained in the final model, it had a nonsignificant effect (ad--justed HR = 0.91; 95% CI = 0.26-3.13), but it appeared to influence marginally the effect of treatment, yielding an ad--justed HR for treatment failure of 2.35 (95% CI = 0.85-6.53; P = 0.101) for patients treated with standard melarso--prol and 6.32 (95% CI = 1.90-20.97; P = 0.003) for patients receiving shortcourse melarsoprol.
Discussion
When compared with eflornithine both regimens of melarsoprol were associ--ated with higher mortality and a higher cumulated incidence of relapse among patients treated for late-stage Gambian trypanosomiasis. Our data confirm the general consensus that eflornithine is safer than melarsoprol, even when used in routine practice. The cumulated incidences of relapse, though likely to be underestimated, were unacceptably high for both melarsoprol regimens.
In particular the short-course regimen performed particularly poorly. Given a treatment failure rate of around 14%, we believe that resistance to melarsop--rol therapy is a considerable obstacle to the control of sleeping sickness in the Republic of the Congo. Our data have certain limitations. The non-randomized nature of our study makes it difficult to truly com--pare treatments, even when differences, such as age, presence of parasites and cerebrospinal fluid white cell counts, are adjusted for. Moreover, data were retrospective and collected from an op--erational programme not a research pro--gramme. However, there are significant challenges involved in implementing and conducting randomized controlled trials of treatment for this disease. Thus there is a scarcity of published data on the use of melarsoprol and eflornithine outside routine care, and there has been only one study published that directly compares the two drugs (melarsoprol and eflornithine). 12 We therefore be--lieve this makes our study relevant and worthwhile.
Another limitation of our study is the generally low rate of follow-up. Our rates are similar to those of other studies, reflecting the real difficulty of tracing pa--tients in resource-poor environments. However, follow-up rates for patients treated with the standard melarsoprol regimen and with eflornithine were similar, allowing us to compare the two. It is difficult to predict the implications of loss to follow-up, but it seems prob--lematic to assume that all those who were lost were actually cured. This would imply that all patients who relapsed were followed-up, so it inevitably leads to an underestimate of the true rate of relapse. It is possible that many patients who relapsed may not have wished to return for follow-up. Additionally, deaths that resulted from relapses may also have been included in the category of those who were lost to follow-up. Also, our follow-up was limited to the first year after treatment. The deliberate decision to change the treatment protocol in our programme is a potential source of bias. However, the baseline characteristics of the two groups would tend to favour a better outcome for those patients treated with melarso--prol. Patients treated with eflornithine tended to have more risk factors for a poor prognosis such as higher white cell count and/or parasitaemia in cerebro--spinal fluid. This bears out anecdotal re--ports from the field that when the choice is available, clinicians are reluctant to use melarsoprol for those patients who are the most unwell. Despite a better base--line profile, the risk of death and relapse was greater in the melarsoprol group.
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Even with these limitations our data still provide useful information on the only drugs available for treating late-stage disease. A literature search identified several prospective studies of each treatment that reported 2-year cure rates of 97% for eflornithine and 86-95% for melarsoprol. [8] [9] [10] [11] [12] 18 How--ever, there is only one large published retrospective non-randomized com--parison of these two drugs. Chappuis et al. showed that eflornithine was safer and caused fewer deaths and adverse events during treatment. 12 However, no statistical difference was seen at 1-year post-treatment, and the follow-up rate at 1 year was 46%.
Apart from melarsoprol's higher tox--icity, the higher cumulated incidence of relapse found in our study would in itself justify reconsidering its use as first-line therapy for late-stage Gambian trypano--somiasis in the Republic of the Congo. However, this analysis is important for two other reasons. First, little data has been published in support of the new short-course melarsoprol regimen. [9] [10] [11] This new regimen has been justified on the basis of its superiority in terms of clinical implementation rather than of efficacy. The risk of relapse due to drug resistance is therefore likely to be no better with short-course melarsoprol. Indeed, in our small cohort, relapse levels were similar when the short-course was compared with the standard regimen. Short-course melarsoprol is therefore unlikely to solve the problem of the high relapse rate in the Republic of the Congo.
Second, Pepin and Mpia have re--ported in a longitudinal study that they found no evidence of a change in me--larsoprol resistance over 20 years. 18 This would seem to offer some reassurance to those who continue to use melarsoprol. However, the authors made no direct comparison between melarsoprol and eflornithine, and hence this result must be viewed with some caution.
Because melarsoprol has low cure rates at 1 year, it appears that eflornithine is the better treatment option for new cases of late-stage disease. It has often been argued that eflornithine is difficult to administer in resource-poor settings because patients require a higher level of nursing care. Additional costs related to eflornithine administration (for drip sets, saline infusions, intravenous cath--eters) are also seen as another hurdle to its widespread use. While it is true that infusions have to be prepared every 6 hours, it is our experience that the tech--nical level of nursing care required has been overestimated. The main priorities in administering eflornithine are to ensure that all infusions are prepared and given regularly in a sterile man--ner. 12 However, patients on eflornithine experience far fewer adverse events than those on melarsoprol; thus the level of nursing care required beyond the prepa--ration and administration of infusions is considerably less than with melarsoprol treatment, during which patients who experience encephalopathy reactions require intensive nursing care. Hence, the presence of 24-hour nursing care to provide night infusions is probably the more important factor that keeps eflo--rnithine from being used more widely. We therefore recommend eflornithine for first-line treatment of the disease in the Republic of the Congo. We also recommend that the additional materials (including saline infusions, drip sets and intravenous catheters) required for the administration of eflornithine should be provided free as part of the current eflornithine donation project under which the drugs are provided free by manufacturers to WHO to be distrib--uted to affected countries.
Future research into the treatment of African trypanosomiasis should look at combination treatments to improve the efficacy of treatment and delay the devel--opment of resistance to eflornithine. A trial of nifurtimox plus eflornithine com--bination therapy has been undertaken in our centres in the Republic of the Congo (comparing eflornithine 100mg/kg ad--ministered intravenously 4 times a day for 14 days versus eflornithine 200mg/kg administered intravenously 2 times a day for 7 days plus nifurtimox 15mg/kg a day divided in 3 doses for 10 days). Data from the study will be published in the future (U Karunakara and G Priotto, personal communication, 2005). Further trials examining this combination treat--ment are being undertaken at other study sites. This combination offers the advan--tage of limiting eflornithine infusions to twice a day. We believe this would be an excellent regimen if safety and efficacy can be demonstrated. It will be a useful interim regimen until new molecules are developed and available for use.
Conclusion
In the Republic of the Congo, the ef--fectiveness of melarsoprol is insufficient to justify its continued use as first-line treatment. We recommend administer--ing a 14-day course of eflornithine as first-line treatment until better treatment regimens are available. O
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